

Letter sent by French National Railway Company's Assurance and Pension Fund (CPR SNCF) to insured women

Our translation from French

Si vous ne parvenez pas à lire cet e-mail, cliquez [ici](#)



Caisse de Prévoyance et de Retraite du personnel de la SNCF

BREAST CANCER: better screening for better treatment

Learn about MyPeBS, a large study on personalized breast cancer screening.

Madam,

Breast cancer is the most common cancer in women, with 360,000 new cases diagnosed and 92,000 deaths each year in Europe. However, if detected early enough, it is curable.

Today, mammography screening is recommended every two years for women over the age of 50.

When it comes to the risk of breast cancer, however, not all women are the same.

This is why the **European study MyPeBS* (My Personal Breast Cancer Screening) proposes adapting screening frequency and modalities to each woman's personal risk profile beginning at age of 40.**

To evaluate this new screening strategy, participants in this clinical study are randomly assigned (via computer draw) to **either the standard screening schedule or the personalized screening schedule for four years, based on their personal risk for breast cancer.**

The researchers will compare these two groups of women to see whether personalized screening could be more effective than the current organized screening.

If you are between the ages of 40 and 70, have never had breast cancer, and would like to participate in MyPeBS, visit www.mypebs.fr

CPR is a partner in this study. By taking part in MyPeBS, you could help improve breast cancer screening in Europe.

* The MyPeBS study is supported by UNICANCER, non-profit public interest healthcare and research organization in France. MyPeBS is supported by the French National Health Insurance and the French National Cancer Institute (INCa) and has been approved by the Strategic Committee for Cancer Screening chaired by the General Director of Health. MyPeBS has received funding from the European Union as part of the Horizon 2020 research and innovation program - grant agreement no. 755394.

